Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -34.86% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.19
- NO KEY NEGATIVE TRIGGERS
2
Risky -
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CAD 9 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.45
75.01%
-8.75
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.17%
0%
4.17%
6 Months
4.17%
0%
4.17%
1 Year
-26.47%
0%
-26.47%
2 Years
25.0%
0%
25.0%
3 Years
150.0%
0%
150.0%
4 Years
-33.33%
0%
-33.33%
5 Years
-33.33%
0%
-33.33%
Frequency Exchange Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.51%
EBIT Growth (5y)
-34.86%
EBIT to Interest (avg)
-1.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.27
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.75
EV to EBIT
-9.21
EV to EBITDA
-9.21
EV to Capital Employed
-9.21
EV to Sales
7.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.30
0.30
Operating Profit (PBDIT) excl Other Income
-0.10
-0.20
50.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.10
-0.20
50.00%
Operating Profit Margin (Excl OI)
-455.40%
-802.60%
34.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs 50.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 50.00% vs 33.33% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1.00
0.80
25.00%
Operating Profit (PBDIT) excl Other Income
-1.10
-1.40
21.43%
Interest
0.00
0.10
-100.00%
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-1.20
-1.40
14.29%
Operating Profit Margin (Excl OI)
-1,088.90%
-1,713.00%
62.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.00% vs 14.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 14.29% vs 71.43% in Dec 2023
About Frequency Exchange Corp. 
Frequency Exchange Corp.
Pharmaceuticals & Biotechnology
Israel Capital Canada Corp is a Canada-based capital-pool company. The Company is formed for the purpose of identifying and evaluating businesses and assets with a view of qualifying transactions. The Company is not engaged in any commercial operations.






